4

Changes in Ownership

Denali Therapeutics Inc. Filed 2017-12-12 Acc 0001209191-17-065249

Director acquired 249,998 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Insider	Date	Transaction	Shares	Price	Value	Owned after	D/I
Schenkein David P Director	2017-12-12	Conversion	+105,225			105,225	I
Schenkein David P Director	2017-12-12	Conversion	+19,774			19,774	I
Schenkein David P Director	2017-12-12	Conversion	+105,225			105,225	I
Schenkein David P Director	2017-12-12	Conversion	+19,774			19,774	I
Derivatives
Schenkein David P Director	2017-12-12	Conversion · Series A-1 Preferred Stock	−105,225			0	I
Schenkein David P Director	2017-12-12	Conversion · Series A-1 Preferred Stock	−19,774			0	I
Schenkein David P Director	2017-12-12	Conversion · Series A-1 Preferred Stock	−105,225			0	I
Schenkein David P Director	2017-12-12	Conversion · Series A-1 Preferred Stock	−19,774			0	I